ENGN (enGene Holdings Inc.) חוב לטווח קצר להון

This GURU.Markets price chart for enGene Holdings Inc. (ENGN) reflects a debt-to-equity ratio of 0.00. The firm's technological advantage is secured by patents for mucosal drug delivery methods. The business model relies on developing non-viral, unconventional therapies for bladder cancer, while human capital is sustained by attracting leading immunologists through a long-term incentive system.

Developing a unique non-viral gene delivery platform requires significant investment in R&D and FDA certification. Analyzing the short-term debt-to-market cap chart, an investor assesses the proportion of current liabilities relative to the company's equity. This metric measures the business's dependence on rapid refinancing and the risk of liquidity loss. The stability of this ratio confirms the financial resilience of enGene Holdings Inc. (ENGN) within the highly competitive biopharmaceutical sector.